Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1101398 | 1.00 | EPHX1 (0.39) | EPHX1THRBATML3MBTL1ALDH1A1 | |
| SCHEMBL27523629 | 0.86 | THRB (0.42) | EPHX1THRBATML3MBTL1ALDH1A1 | |
| SCHEMBL27335896 | 0.82 | LTA4H (0.36) | EPHX1THRBATML3MBTL1ALDH1A1 | |
| SCHEMBL27337149 | 0.82 | SMN1; SMN2 (0.46) | EPHX1THRBATML3MBTL1ALDH1A1 | |
| SCHEMBL489097 | 0.80 | RNPEP (0.43) | ALDH1A1CPA1 | |
| SCHEMBL489096 | 0.80 | RNPEP (0.43) | ALDH1A1CPA1 | |
| SCHEMBL1258031 | 0.80 | RNPEP (0.43) | ALDH1A1CPA1 | |
| SCHEMBL7546509 | 0.77 | EPHX2 (0.46) | EPHX1ALDH1A1CPA1SMN1; SMN2RAB9A | |
| Leucine SCHEMBL3724837 | 0.75 | SLC7A5 (0.60) | EPHX1THRBATML3MBTL1ALDH1A1 | |
| Leucine SCHEMBL3724834 | 0.75 | SLC7A5 (0.60) | EPHX1THRBATML3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153675-B2 | Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid | THERAVANCE, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110224272-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | THERAVANCE, INC. (US) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224272-A1 | CRYSTALLINE FORM OF AN ALKOXYIMIDAZOL-1-YLMETHYL BIPHENYL CARBOXYLIC ACID | FFAR1, FFAR3, FFAR2 | EPHX1 2320/4885THRB 3516/4885ATM 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.